Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912333762> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2912333762 abstract "Introduction: Rising drug costs have sparked interest in tying payments to outcomes to reduce payer risk of adopting low-value interventions. However, performance-linked reimbursement (PLR) plans are poorly understood. We modeled the effects of PLR plans on the distribution of therapy value obtained using sacubitril-valsartan as an illustrative case. Methods: We modeled PLR plans that issued refunds/discounts based on reductions in cardiovascular mortality or heart failure hospitalization. We used probabilistic sensitivity analyses from a published cost-effectiveness model of sacubitril-valsartan to model real-world uncertainty. We compared the distribution of value obtained (net monetary benefit [NMB]) with PLR plans and conventional payment across 10,000 paired simulations. Price premiums were set so average reimbursement was equal with both schemes. We varied plan structure and treatment/population uncertainty. With successful plans, payment would decrease in simulations with less benefit and increase with more benefit - decreasing the NMB standard deviation. We also calculated incremental NMBs as valuations of the change in NMB variability using a risk-averse utility curve. Results: A plan that adjusted drug reimbursement based on the ratio of observed to expected reduction of cardiovascular mortality reduced the standard deviation of NMB by 16.6% (Table 1). The incremental NMB - an estimate of per-patient value of implementing the PLR plan - was only $35, 3.3% of the NMB with conventional payment. Cardiovascular mortality plans were more successful than heart failure hospitalization plans. With rare outcomes, refunds based on cohort event rates were larger than refunds for individual adverse events. Plans improved with greater treatment effect uncertainty, larger refunds, and more payer risk-aversion. Their value decreased with more natural history uncertainty. Plans unraveled if the payer asymmetrically selected higher risk patients. Conclusion: PLR plans require outcomes tightly associated with treatment value and minimally influenced by unrelated uncertainty. Both sides must agree on a predictable population and limit asymmetric selection. For rare outcomes, plans should evaluate population event rates or surrogate measures that consistently reflect the clinical benefit." @default.
- W2912333762 created "2019-02-21" @default.
- W2912333762 creator A5029257839 @default.
- W2912333762 creator A5079556755 @default.
- W2912333762 date "2018-04-01" @default.
- W2912333762 modified "2023-10-16" @default.
- W2912333762 title "Abstract 143: Pearls and Pitfalls of Performance-linked Reimbursement Plans for Novel Drugs: The Case of Sacubitril-Valsartan" @default.
- W2912333762 doi "https://doi.org/10.1161/circoutcomes.11.suppl_1.143" @default.
- W2912333762 hasPublicationYear "2018" @default.
- W2912333762 type Work @default.
- W2912333762 sameAs 2912333762 @default.
- W2912333762 citedByCount "0" @default.
- W2912333762 crossrefType "journal-article" @default.
- W2912333762 hasAuthorship W2912333762A5029257839 @default.
- W2912333762 hasAuthorship W2912333762A5079556755 @default.
- W2912333762 hasConcept C10138342 @default.
- W2912333762 hasConcept C126322002 @default.
- W2912333762 hasConcept C144133560 @default.
- W2912333762 hasConcept C145097563 @default.
- W2912333762 hasConcept C160735492 @default.
- W2912333762 hasConcept C162118730 @default.
- W2912333762 hasConcept C162324750 @default.
- W2912333762 hasConcept C194828623 @default.
- W2912333762 hasConcept C2775999527 @default.
- W2912333762 hasConcept C2777387769 @default.
- W2912333762 hasConcept C2779703844 @default.
- W2912333762 hasConcept C2908647359 @default.
- W2912333762 hasConcept C50522688 @default.
- W2912333762 hasConcept C71924100 @default.
- W2912333762 hasConcept C72563966 @default.
- W2912333762 hasConcept C84393581 @default.
- W2912333762 hasConcept C99454951 @default.
- W2912333762 hasConceptScore W2912333762C10138342 @default.
- W2912333762 hasConceptScore W2912333762C126322002 @default.
- W2912333762 hasConceptScore W2912333762C144133560 @default.
- W2912333762 hasConceptScore W2912333762C145097563 @default.
- W2912333762 hasConceptScore W2912333762C160735492 @default.
- W2912333762 hasConceptScore W2912333762C162118730 @default.
- W2912333762 hasConceptScore W2912333762C162324750 @default.
- W2912333762 hasConceptScore W2912333762C194828623 @default.
- W2912333762 hasConceptScore W2912333762C2775999527 @default.
- W2912333762 hasConceptScore W2912333762C2777387769 @default.
- W2912333762 hasConceptScore W2912333762C2779703844 @default.
- W2912333762 hasConceptScore W2912333762C2908647359 @default.
- W2912333762 hasConceptScore W2912333762C50522688 @default.
- W2912333762 hasConceptScore W2912333762C71924100 @default.
- W2912333762 hasConceptScore W2912333762C72563966 @default.
- W2912333762 hasConceptScore W2912333762C84393581 @default.
- W2912333762 hasConceptScore W2912333762C99454951 @default.
- W2912333762 hasIssue "suppl_1" @default.
- W2912333762 hasLocation W29123337621 @default.
- W2912333762 hasOpenAccess W2912333762 @default.
- W2912333762 hasPrimaryLocation W29123337621 @default.
- W2912333762 hasRelatedWork W124895621 @default.
- W2912333762 hasRelatedWork W2099726527 @default.
- W2912333762 hasRelatedWork W215892325 @default.
- W2912333762 hasRelatedWork W2284427628 @default.
- W2912333762 hasRelatedWork W2352274781 @default.
- W2912333762 hasRelatedWork W2902316328 @default.
- W2912333762 hasRelatedWork W2907038338 @default.
- W2912333762 hasRelatedWork W2912333762 @default.
- W2912333762 hasRelatedWork W3030968064 @default.
- W2912333762 hasRelatedWork W4205760870 @default.
- W2912333762 hasVolume "11" @default.
- W2912333762 isParatext "false" @default.
- W2912333762 isRetracted "false" @default.
- W2912333762 magId "2912333762" @default.
- W2912333762 workType "article" @default.